Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord Biotech's EBIT per Share for the
three
months ended in Jun. 2026 was ₹7.49.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹34.81.
During the past 12 months, the average EBIT per Share Growth Rate of Concord Biotech was -26.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 6.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Concord Biotech's EBIT per Share or its related term are showing as below:
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Concord Biotech was 25.20% per year. The lowest was 0.00% per year. And the median was 12.25% per year.
BOM:543960's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.45 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Concord Biotech's EBIT for the
three
months ended in Jun. 2026 was ₹784 Mil.
Concord Biotech (BOM:543960) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Concord Biotech EBIT per Share Related Terms
Concord Biotech EBIT per Share Historical Data
* Premium members only.
The historical data trend for Concord Biotech's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹34.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Biotech (BOM:543960) has a EBIT per Share of ₹34.81 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Concord Biotech and its competitors. According to the industry distribution chart, Concord Biotech ranks #999999 out of 1168 companies in the Biotechnology industry.
Is Concord Biotech's EBIT per Share too high?
Concord Biotech's current EBIT per Share is ₹34.81. Based on the distribution chart, Concord Biotech ranks #999999 out of 1168 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Concord Biotech has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #999999 out of 1168 companies for EBIT per Share. This places Concord Biotech in the lower half of its industry. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current EBIT per Share is ₹34.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,670.71, compared to a current price of ₹1,446.10 — trading 13.4% below its estimated fair value. The current EBIT per Share is ₹34.81. Concord Biotech's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current EBIT per Share is ₹34.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,446.10 is trading 13.4% below its estimated GF Value™ of ₹1,670.71.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
EBIT per Share: ₹34.81
GF Value™: ₹1,670.71 vs. price of ₹1,446.10 (13.4% below fair value)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
90GF Score
Get the complete analysis for BOM:543960
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
